AGP Executive Report
Last update: 3 hours agoCancer Drug Update: The FDA accepted a supplemental biologics license application for a subcutaneous mosunetuzumab (Lunsumio VELO) plus polatuzumab vedotin (Polivy) regimen for adults with relapsed/refractory large B-cell lymphoma after at least one prior therapy, with an FDA decision date set for Feb 9, 2027; phase 3 SUNMO data showed a major reduction in risk of progression or death versus an R-based comparator. Blood Safety & Lab Practice: Experts at EHA 2026 discussed how monoclonal antibodies can interfere with transfusion testing, complicating compatibility work and potentially affecting patient care. Drug-Drug Interaction Watch: Early phase results for the BTK degrader BGB-16673 suggest a low risk of clinically relevant CYP3A-mediated interactions, which could mean more flexible dosing. Maternal Health Access: Global midwife leaders warned that visa rejections blocked key experts from a major congress in Lisbon, undermining progress on preventing avoidable mother and baby deaths. Heat & Sports Health: A Guardian analysis found some World Cup matches were played in severe heat stress conditions, raising concerns about player safety and whether games should be delayed. Sweden Tech & Care Connectivity: Sweden’s telecom regulator notes Telia plans to shut down 2G by end-2027, with healthcare and social care among the sectors affected.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[BGB-16673 Has Low Risk of CYP3A-Mediated Drug-Drug Interactions in Healthy Volunteers in Phase 1 Studies]]>](https://cdn.sanity.io/images/0vv8moc6/onclive/a33b9e88f9f062855b35d580310999c42eb622ca-1280x720.jpg)
